A drug that has recently been approved for the treatment of schizophrenia could one day be prescribed to Alzheimer’s patients ...

The US FDA has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, ...

Anavex Life Sciences (AVXL) stock rises 10% in premarket as company submits EU marketing application for Alzheimer's drug ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, ...

The "Dementia Associated With Alzheimer's Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Dementia Associated With Alzheimer's Disease - ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

KarXT - Nicola Rizzo Pesci and Andrea Cipriani summarise findings from the EMERGENT-2 trial spotlighting a promising new ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Vanderbilt University has described muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, sleep disorders ...

Antipsychotics can also cause weight gain, metabolic dysfunction, and hormonal problems. Activating muscarinic receptors in the brain can help schizophrenia symptoms. Emraclidine acts on the ...